IRESSA治疗晚期非小细胞肺癌的研究进展  

Research on Progress of IRESSA in Advanced Non-small cell Lung Cancer

作　　者：韩宇[1] 徐建明[1] 宋三泰[1] 

机构地区：[1]军事医学科学院附属医院肿瘤中心,北京市100071

出　　处：《中国肿瘤临床》2006年第2期111-114,共4页Chinese Journal of Clinical Oncology

摘　　要：IRESSA(ZD1839,Gefitinib)作为一种能口服的小分子EGFR酪氨酸激酶抑制剂,已在多个国家获准上市,用于治疗化疗失败的晚期非小细胞肺癌。随着IRESSA的临床广泛应用和研究的逐步深入,如何选择对IRESSA敏感的患者,充分发挥其靶向性,是近年来探索如何提高IRESSA疗效的热点。本文从IRESSA疗效与患者特征、IRESSA疗效与EGFR及其下游因子的表达水平,以及IRESSA疗效与EGFR突变三个方面,将近几年的研究进展综述如下。IRESSA （ZD1839, Gefitinib）, an orally selective drug inhibitor of the epidermal growth factor receptor （EGFR） tyrosine kinase （TK）, have been approved in the management of patients with advanced, chemotherapy-refractory non-small cell lung cancer （NSCLC） in several countries. Recently, how to predict the reponse to IRESSA has become a focus on enhancing the clinical effect of IRESSA to NSCLC patients. In this review, we discussed recent progression in three aspects, including patients＇ characteristics and efficacy of IRESSA, the expression of EGFR or its downstream molecules and IRESSA efficacy, and the mutational status of EGFR and IRESSA efficacy.

关 键 词：IRESSA 非小细胞肺癌 预测疗效 

分 类 号：R734.2[医药卫生—肿瘤]